Document is current
Any future updates will be listed below
-
Authors
Glasgow, Russell E. https://orcid.org/0000-0003-4218-3231
Knoepke, Christopher E.
Magid, David
Grunwald, Gary K.
Glorioso, Thomas J.
Waughtal, Joy
Marrs, Joel C.
Bull, Sheana
Ho, P. Michael
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (4UH3HL144163-02)
- License Information
-
More Information
Article History
Received: 5 December 2020
Accepted: 13 July 2021
First Online: 11 August 2021
Declarations
:
: All patients who are eligible are automatically enrolled unless they opt out. Once a participant has been identified as eligible for enrollment, they are sent a letter in the US mail describing the study, the eligibility criteria, and the process for automatic enrollment. A copy of this letter is provided as Additional file. At that time, they are given instructions about how they may opt out if they do not want to participate. There is a second opportunity for them to opt out. If they are flagged from system pharmacy records as not having filled a prescription for management of their cardiovascular condition, they will be assigned at random to a study arm and may begin receiving messages via text. At that time, they are notified that they can opt out by texting “STOP” in response to any message.This study was reviewed and approved by the Colorado Multiple Institutional Review Board, protocol number 18-2779.
: Not applicable
: The authors declare that they have no competing interests.
